By Yair Holtzman, Gleb Gorkhover, and Michael Ganz
While the United States currently holds the largest share of worldwide medtech sales, it cannot afford to rest on its laurels.
The coming years will be critical in determining if the U.S. medtech industry can take stave off competition from foreign and consumer technology players while taking advantage of existing strengths.
Success will depend in part on how proactive U.S. firms are in embracing a value-added services model combining first-class products with complementary services and software to improve healthcare. This will be the major differentiator between high-end products and commodity items, and companies that thrive and those that become extinct.
Yair Holtzman, CPA,MBA, MS is a partner at Anchin, Block & Anchin LLP (New York City). Reach him at [email protected]
Gleb Gorkhover CPA, MS is a manager at Anchin Block & Anchin LLP.
Michael Ganz BS, MS is a senior at Anchin, Block & Anchin LLP.
THREATS CONTINUE TO THREATS AND OPPORTUNITIES FOR MEDTECH
[image courtesy of SCOTTCHAN/FREEDIGITALPHOTOS.NET]